Open this publication in new window or tab >>Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Gene Technology, Gene Technology.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden.
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Gene Technology, Gene Technology.
Immunology, Infectious Diseases and Ophthalmology (I2O) DTA, Pharma Research & Early Development. Roche Innovation Center, Basel, Switzerland.
Karolinska University Hospital, Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden; Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden.
Immunology, Infectious Diseases and Ophthalmology (I2O) DTA, Pharma Research & Early Development. Roche Innovation Center, Basel, Switzerland.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institute and University Hospital, 171 76, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Center of Molecular Medicine, Karolinska University Hospital, 171 64, Solna, Sweden; SciLifeLab, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Show others...
2026 (English)In: Immunity, ISSN 1074-7613, E-ISSN 1097-4180, Vol. 59, no 6, p. 1599-1615.e5Article in journal (Refereed) Published
Abstract [en]
Inflammatory bowel disease (IBD) is a complex disorder that is often resistant to immunomodulatory treatments. Here, to understand how immune, epithelial, and stromal compartments are rewired during disease initiation and progression, we leveraged T cell transfer and Il10−/− spontaneous colitis models, including anti-IL-12p40 intervention, and integrated time-course transcriptomic analyses at bulk, single-cell, and spatial resolution. These well-established models exhibited conserved features of chronic inflammation, including neutrophil infiltration, and impaired tissue regeneration. Comparison of murine transcriptional programs and human IBD datasets revealed neutrophil-associated inflammation and cytokine signaling as the most conserved pathways across species. We identified spatial heterogeneity in inflammatory modules and described three gene programs with differential spatial and temporal distributions, including one corresponding to tertiary lymphoid structures. When used together, these models recapitulate complementary aspects of human disease at both cellular and transcriptional levels. This high-resolution spatiotemporal atlas will guide future translational research aimed at optimizing therapeutic strategies for IBD.
Place, publisher, year, edition, pages
Elsevier BV, 2026
Keywords
cell circuitry, cell dynamics, chronic colitis, epithelial antigen presentation, inflammatory bowel diseases, murine model, neutrophils, single-cell RNA-seq, spatial transcriptomics, tertiary lymphoid structures
National Category
Gastroenterology and Hepatology Cell and Molecular Biology Immunology in the Medical Area
Identifiers
urn:nbn:se:kth:diva-383500 (URN)10.1016/j.immuni.2026.04.005 (DOI)42097141 (PubMedID)2-s2.0-105040784760 (Scopus ID)
Note
QC 20260615
2026-06-152026-06-152026-06-15Bibliographically approved